Journal
BLOOD
Volume 115, Issue 7, Pages 1331-1342Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2009-11-255455
Keywords
-
Categories
Funding
- National Institutes of Health [CA1809, HL 093294, HL 081595]
- MedImmune
- Novartis
- Sanofi Pasteur
- Adamas Pharmaceuticals
- Roche Pharmaceuticals
- GlaxoSmithKline
- Nexbio Inc
Ask authors/readers for more resources
The 2009 H1N1 influenza pandemic has heightened the interest of clinicians for options in the prevention and management of influenza virus infection in immunocompromised patients. Even before the emergence of the novel 2009 H1N1 strain, influenza disease was a serious complication in patients with hematologic malignancies receiving chemotherapy or undergoing hematopoietic cell transplantation. Here we review the clinical manifestations of seasonal and 2009 H1N1 influenza and discuss current diagnosis, antiviral treatment, and prophylaxis options. We also summarize infection control and vaccination strategies for patients, family members, and caregivers. (Blood. 2010; 115: 1331-1342)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available